Drug Profile
Research programme: NR2B NMDA receptor antagonists - Merck & Co
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Oxadiazoles; Small molecules
- Mechanism of Action NR2B N-Methyl-D-Aspartate antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Neuropathic pain; Parkinson's disease
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Neuropathic-pain in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Parkinson's-disease in USA (PO)
- 03 Sep 2010 Preclinical development is ongoing in USA